MedTrace Logo

The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding

NCT02150447 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 394

Last updated 2018-04-04

No results posted yet for this study

Summary

The aim of this study is the effect of proton pump inhibitor (PPI) with respect to gastric cancer bleeding in inoperable patients.

Conditions

Interventions

DRUG

Proton pump inhibitor

Lansoprazole 30 mg, daily

DRUG

Placebo

Placebo, daily

Sponsors & Collaborators

  • Pusan National University Hospital

    collaborator OTHER

  • Kosin University Gospel Hospital

    collaborator OTHER

  • Gyeongsang National University Hospital

    collaborator OTHER

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Il Ju Choi, M.D., Ph.D. · National Cancer Center, Korea

  • Gwang Ha Kim, M.D., Ph.D. · Pusan National University Hospital

  • Moo In Park, M.D., Ph.D. · Kosin University Gospel Hospital

  • Won Sup Lee, M.D., Ph.D. · Gyeongsang National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2015-04-30
Completion
2017-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02150447 on ClinicalTrials.gov